methionine adenosyltransferase (mat)

AG-270 is an allosteric and orally active inhibitor of MAT2A.

PF-9366 is a human methionine adenosyltransferase 2A (Mat2A) inhibitor with an IC50 of 420 nM and a Kd of 170 nM.

AGI-25696 is an inhibitor of methionine adenosyltransferase 2A (MATA2). AGI-25696 blocks the growth of MTAP-deleted tumors in vivo and can be used for studies about the treatment of cancer.

FIDAS-3, a stilbene derivative and potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A), exhibits anticancer activities by effectively competing with S-adenosylmethionine (SAM) for MAT2A binding.

MAT2A inhibitor 4 is an inhibitor of the catalytic subunit of methionine S-adenosyltransferase-2, which is used in cancer research.

MAT2A Allosteric Inhibitor 1, also known as Compound 5, is a selective inhibitor of methionine adenosyltransferase (MAT) demonstrating potent activity with an IC50 value of 6.8 nM [1].

MAT2A-IN-9, a 2-oxoquinazoline derivative, is a potent MAT2A (methionine adenylyltransferase 2A) inhibitor.MAT2A-IN-9 has antitumor activity for the treatment of lymphomas and solid tumors.

MAT2A Allosteric Inhibitor 2 is a potent, selective inhibitor exhibiting an IC50 of 5 nM and demonstrates nanomolar efficacy (IC50 = 5 μM) in proliferation assays utilizing the MTAP -/- cell line [1].

MAT2A-IN-10 (Compound 28), an orally active inhibitor of MAT2A, exhibits an IC50 of 26 nM and is utilized in cancer research [1].

MAT2A inhibitor 2 is an inhibitor of methionine adenosyltransferase 2A (MAT2A).

AGI-24512 is a potent inhibitor of methionine adenylyltransferase 2α (MAT2A) (IC50: 8 nM).AGI-24512 shows antiproliferative activity in MTAP-deficient cancer cells.AGI-24512 inhibits MAT2A, which causes DNA damage in MTAP, and is often used in conjunction with anticancer compounds in cancer research.